Icalcaprant

Icalcaprant
Clinical data
Other namesCVL-354
Routes of
administration		Oral administration
Drug classOpioid antagonist; κ-Opioid receptor antagonist
Identifiers
  • 4-[4-{{(2S)-2-(3-methoxy-1-methylpyrazol-4-yl)pyrrolidin-1-yl]methyl]phenoxy]benzamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H26N4O3
Molar mass406.486 g·mol−1
3D model (JSmol)
  • CN1C=C(C(=N1)OC)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)N
  • InChI=1S/C23H26N4O3/c1-26-15-20(23(25-26)29-2)21-4-3-13-27(21)14-16-5-9-18(10-6-16)30-19-11-7-17(8-12-19)22(24)28/h5-12,15,21H,3-4,13-14H2,1-2H3,(H2,24,28)/t21-/m0/s1
  • Key:OBDLEFCGVHQDFR-NRFANRHFSA-N

Icalcaprant[1] (developmental code name CVL-354) is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[2][3] It is taken by mouth.[2]

It acts as a selective antagonist of the κ-opioid receptor.[2][3] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.[3]

It was originated by Pfizer and is under development by Cerevel Therapeutics.[2] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[2]

  1. ^ "Icalcaprant (CVL-354)". AbbVie. Retrieved 2024-08-15.
  2. ^ a b c d e "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.
  3. ^ a b c "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.